Cargando…
Improvement of Long COVID symptoms over one year
IMPORTANCE: Early and accurate diagnosis and treatment of Long COVID, clinically known as post-acute sequelae of COVID-19 (PASC), may mitigate progression to chronic diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our objective was to determine the utility of the DePaul...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868805/ https://www.ncbi.nlm.nih.gov/pubmed/36698810 http://dx.doi.org/10.3389/fmed.2022.1065620 |
_version_ | 1784876625882513408 |
---|---|
author | Oliveira, Carlos R. Jason, Leonard A. Unutmaz, Derya Bateman, Lucinda Vernon, Suzanne D. |
author_facet | Oliveira, Carlos R. Jason, Leonard A. Unutmaz, Derya Bateman, Lucinda Vernon, Suzanne D. |
author_sort | Oliveira, Carlos R. |
collection | PubMed |
description | IMPORTANCE: Early and accurate diagnosis and treatment of Long COVID, clinically known as post-acute sequelae of COVID-19 (PASC), may mitigate progression to chronic diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our objective was to determine the utility of the DePaul Symptom Questionnaire (DSQ) to assess the frequency and severity of common symptoms of ME/CFS, to diagnose and monitor symptoms in patients with PASC. METHODS: This prospective, observational cohort study enrolled 185 people that included 34 patients with PASC that had positive COVID-19 test and persistent symptoms of >3 months and 151 patients diagnosed with ME/CFS. PASC patients were followed over 1 year and responded to the DSQ at baseline and 12 months. ME/CFS patients responded to the DSQ at baseline and 1 year later. Changes in symptoms over time were analyzed using a fixed-effects model to compute difference-in-differences estimates between baseline and 1-year follow-up assessments. PARTICIPANTS: Patients were defined as having PASC if they had a previous positive COVID-19 test, were experiencing symptoms of fatigue, post-exertional malaise, or other unwellness for at least 3 months, were not hospitalized for COVID-19, had no documented major medical or psychiatric diseases prior to COVID-19, and had no other active and untreated disease processes that could explain their symptoms. PASC patients were recruited in 2021. ME/CFS patients were recruited in 2017. RESULTS: At baseline, patients with PASC had similar symptom severity and frequency as patients with ME/CFS and satisfied ME/CFS diagnostic criteria. ME/CFS patients experienced significantly more severe unrefreshing sleep and flu-like symptoms. Five symptoms improved significantly over the course of 1 year for PASC patients including fatigue, post-exertional malaise, brain fog, irritable bowel symptoms and feeling unsteady. In contrast, there were no significant symptom improvements for ME/CFS patients. CONCLUSION AND RELEVANCE: There were considerable similarities between patients with PASC and ME/CFS at baseline. However, symptoms improved for PASC patients over the course of a year but not for ME/CFS patients. PASC patients with significant symptom improvement no longer met ME/CFS clinical diagnostic criteria. These findings indicate that the DSQ can be used to reliably assess and monitor PASC symptoms. |
format | Online Article Text |
id | pubmed-9868805 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-98688052023-01-24 Improvement of Long COVID symptoms over one year Oliveira, Carlos R. Jason, Leonard A. Unutmaz, Derya Bateman, Lucinda Vernon, Suzanne D. Front Med (Lausanne) Medicine IMPORTANCE: Early and accurate diagnosis and treatment of Long COVID, clinically known as post-acute sequelae of COVID-19 (PASC), may mitigate progression to chronic diseases such as myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). Our objective was to determine the utility of the DePaul Symptom Questionnaire (DSQ) to assess the frequency and severity of common symptoms of ME/CFS, to diagnose and monitor symptoms in patients with PASC. METHODS: This prospective, observational cohort study enrolled 185 people that included 34 patients with PASC that had positive COVID-19 test and persistent symptoms of >3 months and 151 patients diagnosed with ME/CFS. PASC patients were followed over 1 year and responded to the DSQ at baseline and 12 months. ME/CFS patients responded to the DSQ at baseline and 1 year later. Changes in symptoms over time were analyzed using a fixed-effects model to compute difference-in-differences estimates between baseline and 1-year follow-up assessments. PARTICIPANTS: Patients were defined as having PASC if they had a previous positive COVID-19 test, were experiencing symptoms of fatigue, post-exertional malaise, or other unwellness for at least 3 months, were not hospitalized for COVID-19, had no documented major medical or psychiatric diseases prior to COVID-19, and had no other active and untreated disease processes that could explain their symptoms. PASC patients were recruited in 2021. ME/CFS patients were recruited in 2017. RESULTS: At baseline, patients with PASC had similar symptom severity and frequency as patients with ME/CFS and satisfied ME/CFS diagnostic criteria. ME/CFS patients experienced significantly more severe unrefreshing sleep and flu-like symptoms. Five symptoms improved significantly over the course of 1 year for PASC patients including fatigue, post-exertional malaise, brain fog, irritable bowel symptoms and feeling unsteady. In contrast, there were no significant symptom improvements for ME/CFS patients. CONCLUSION AND RELEVANCE: There were considerable similarities between patients with PASC and ME/CFS at baseline. However, symptoms improved for PASC patients over the course of a year but not for ME/CFS patients. PASC patients with significant symptom improvement no longer met ME/CFS clinical diagnostic criteria. These findings indicate that the DSQ can be used to reliably assess and monitor PASC symptoms. Frontiers Media S.A. 2023-01-09 /pmc/articles/PMC9868805/ /pubmed/36698810 http://dx.doi.org/10.3389/fmed.2022.1065620 Text en Copyright © 2023 Oliveira, Jason, Unutmaz, Bateman and Vernon. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Medicine Oliveira, Carlos R. Jason, Leonard A. Unutmaz, Derya Bateman, Lucinda Vernon, Suzanne D. Improvement of Long COVID symptoms over one year |
title | Improvement of Long COVID symptoms over one year |
title_full | Improvement of Long COVID symptoms over one year |
title_fullStr | Improvement of Long COVID symptoms over one year |
title_full_unstemmed | Improvement of Long COVID symptoms over one year |
title_short | Improvement of Long COVID symptoms over one year |
title_sort | improvement of long covid symptoms over one year |
topic | Medicine |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9868805/ https://www.ncbi.nlm.nih.gov/pubmed/36698810 http://dx.doi.org/10.3389/fmed.2022.1065620 |
work_keys_str_mv | AT oliveiracarlosr improvementoflongcovidsymptomsoveroneyear AT jasonleonarda improvementoflongcovidsymptomsoveroneyear AT unutmazderya improvementoflongcovidsymptomsoveroneyear AT batemanlucinda improvementoflongcovidsymptomsoveroneyear AT vernonsuzanned improvementoflongcovidsymptomsoveroneyear |